- Home
- LPSN vs RGLS Comparison
LPSN vs RGLS Comparison
Compare LPSN & RGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPSN
- RGLS
- Stock Information
- Founded
- LPSN 1995
- RGLS 2007
- Country
- LPSN United States
- RGLS United States
- Employees
- LPSN N/A
- RGLS N/A
- Industry
- LPSN EDP Services
- RGLS Biotechnology: Pharmaceutical Preparations
- Sector
- LPSN Technology
- RGLS Health Care
- Exchange
- LPSN Nasdaq
- RGLS Nasdaq
- Market Cap
- LPSN 122.6M
- RGLS 102.1M
- IPO Year
- LPSN 2000
- RGLS 2012
- Fundamental
- Price
- LPSN $1.36
- RGLS $1.26
- Analyst Decision
- LPSN Hold
- RGLS Strong Buy
- Analyst Count
- LPSN 6
- RGLS 6
- Target Price
- LPSN $1.18
- RGLS $10.33
- AVG Volume (30 Days)
- LPSN 7.8M
- RGLS 315.1K
- Earning Date
- LPSN 02-26-2025
- RGLS 03-20-2025
- Dividend Yield
- LPSN N/A
- RGLS N/A
- EPS Growth
- LPSN N/A
- RGLS N/A
- EPS
- LPSN N/A
- RGLS N/A
- Revenue
- LPSN $334,736,000.00
- RGLS N/A
- Revenue This Year
- LPSN N/A
- RGLS N/A
- Revenue Next Year
- LPSN N/A
- RGLS N/A
- P/E Ratio
- LPSN N/A
- RGLS N/A
- Revenue Growth
- LPSN N/A
- RGLS N/A
- 52 Week Low
- LPSN $0.45
- RGLS $1.15
- 52 Week High
- LPSN $3.29
- RGLS $3.79
- Technical
- Relative Strength Index (RSI)
- LPSN 57.45
- RGLS 35.32
- Support Level
- LPSN $1.27
- RGLS $1.24
- Resistance Level
- LPSN $1.43
- RGLS $1.40
- Average True Range (ATR)
- LPSN 0.22
- RGLS 0.11
- MACD
- LPSN -0.01
- RGLS -0.03
- Stochastic Oscillator
- LPSN 33.33
- RGLS 19.15
About LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation.. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.